Effects of captopril on factors affecting gastric mucosal integrity in aspirin-induced gastric lesions in Sprague-Dawley rats

Nafeeza Mohd Ismail, Ibrahim Abdel Aziz Ibrahim, Najihah Binti Mohd Hashim, Kamsiah Jaarin

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Introduction: Captopril is an angiotensin-converting enzyme inhibitor, which is used as an antihypertensive agent and has shown antioxidant properties. This study aims at determining the effects of captopril on factors affecting gastric mucosal integrity in aspirin-induced gastric lesions. Material and methods: Eighteen male Sprague-Dawley (200-250 g) rats that were given aspirin (40 mg/100 g body weight) were divided into three groups: the control, captopril (1 mg/100 g body weight daily) and ranitidine (2.5 mg/100 g body weight twice daily) groups. Ranitidine and captopril were given orally for 28 days. Rats in all groups were sacrificed and the parameters measured. Results: Captopril reduced gastric acidity, and increased gastric glutathione (GSH) and prostaglandin E2 (PGE2) significantly in comparison to the control group. Captopril also reduced malondialdehyde (MDA) and gastric lesions insignificantly compared to the control group. Ranitidine healed the lesions significantly compared to the control group. There was no difference between ranitidine and captopril on the severity of lesions, gastric acidity, MDA and GSH. Captopril increased PGE2 compared to ranitidine (p < 0.05). Conclusions: Captopril has desirable effects on the factors affecting gastric mucosal integrity (acidity, PGE2 and GSH) and is comparable to ranitidine in ulcer healing.

Original languageEnglish
Pages (from-to)1132-1137
Number of pages6
JournalArchives of Medical Science
Volume9
Issue number6
DOIs
Publication statusPublished - Dec 2013

Fingerprint

Captopril
Aspirin
Sprague Dawley Rats
Stomach
Ranitidine
Dinoprostone
Glutathione
Control Groups
Body Weight
Malondialdehyde
Angiotensin-Converting Enzyme Inhibitors
Antihypertensive Agents
Ulcer
Antioxidants

Keywords

  • Aspirin
  • Captopril
  • Gastric lesions
  • Ranitidine

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Effects of captopril on factors affecting gastric mucosal integrity in aspirin-induced gastric lesions in Sprague-Dawley rats. / Ismail, Nafeeza Mohd; Ibrahim, Ibrahim Abdel Aziz; Hashim, Najihah Binti Mohd; Jaarin, Kamsiah.

In: Archives of Medical Science, Vol. 9, No. 6, 12.2013, p. 1132-1137.

Research output: Contribution to journalArticle

Ismail, Nafeeza Mohd ; Ibrahim, Ibrahim Abdel Aziz ; Hashim, Najihah Binti Mohd ; Jaarin, Kamsiah. / Effects of captopril on factors affecting gastric mucosal integrity in aspirin-induced gastric lesions in Sprague-Dawley rats. In: Archives of Medical Science. 2013 ; Vol. 9, No. 6. pp. 1132-1137.
@article{df6939fd0dcb474091e4433e19e894db,
title = "Effects of captopril on factors affecting gastric mucosal integrity in aspirin-induced gastric lesions in Sprague-Dawley rats",
abstract = "Introduction: Captopril is an angiotensin-converting enzyme inhibitor, which is used as an antihypertensive agent and has shown antioxidant properties. This study aims at determining the effects of captopril on factors affecting gastric mucosal integrity in aspirin-induced gastric lesions. Material and methods: Eighteen male Sprague-Dawley (200-250 g) rats that were given aspirin (40 mg/100 g body weight) were divided into three groups: the control, captopril (1 mg/100 g body weight daily) and ranitidine (2.5 mg/100 g body weight twice daily) groups. Ranitidine and captopril were given orally for 28 days. Rats in all groups were sacrificed and the parameters measured. Results: Captopril reduced gastric acidity, and increased gastric glutathione (GSH) and prostaglandin E2 (PGE2) significantly in comparison to the control group. Captopril also reduced malondialdehyde (MDA) and gastric lesions insignificantly compared to the control group. Ranitidine healed the lesions significantly compared to the control group. There was no difference between ranitidine and captopril on the severity of lesions, gastric acidity, MDA and GSH. Captopril increased PGE2 compared to ranitidine (p < 0.05). Conclusions: Captopril has desirable effects on the factors affecting gastric mucosal integrity (acidity, PGE2 and GSH) and is comparable to ranitidine in ulcer healing.",
keywords = "Aspirin, Captopril, Gastric lesions, Ranitidine",
author = "Ismail, {Nafeeza Mohd} and Ibrahim, {Ibrahim Abdel Aziz} and Hashim, {Najihah Binti Mohd} and Kamsiah Jaarin",
year = "2013",
month = "12",
doi = "10.5114/aoms.2012.31252",
language = "English",
volume = "9",
pages = "1132--1137",
journal = "Archives of Medical Science",
issn = "1734-1922",
publisher = "Termedia Publishing House Ltd.",
number = "6",

}

TY - JOUR

T1 - Effects of captopril on factors affecting gastric mucosal integrity in aspirin-induced gastric lesions in Sprague-Dawley rats

AU - Ismail, Nafeeza Mohd

AU - Ibrahim, Ibrahim Abdel Aziz

AU - Hashim, Najihah Binti Mohd

AU - Jaarin, Kamsiah

PY - 2013/12

Y1 - 2013/12

N2 - Introduction: Captopril is an angiotensin-converting enzyme inhibitor, which is used as an antihypertensive agent and has shown antioxidant properties. This study aims at determining the effects of captopril on factors affecting gastric mucosal integrity in aspirin-induced gastric lesions. Material and methods: Eighteen male Sprague-Dawley (200-250 g) rats that were given aspirin (40 mg/100 g body weight) were divided into three groups: the control, captopril (1 mg/100 g body weight daily) and ranitidine (2.5 mg/100 g body weight twice daily) groups. Ranitidine and captopril were given orally for 28 days. Rats in all groups were sacrificed and the parameters measured. Results: Captopril reduced gastric acidity, and increased gastric glutathione (GSH) and prostaglandin E2 (PGE2) significantly in comparison to the control group. Captopril also reduced malondialdehyde (MDA) and gastric lesions insignificantly compared to the control group. Ranitidine healed the lesions significantly compared to the control group. There was no difference between ranitidine and captopril on the severity of lesions, gastric acidity, MDA and GSH. Captopril increased PGE2 compared to ranitidine (p < 0.05). Conclusions: Captopril has desirable effects on the factors affecting gastric mucosal integrity (acidity, PGE2 and GSH) and is comparable to ranitidine in ulcer healing.

AB - Introduction: Captopril is an angiotensin-converting enzyme inhibitor, which is used as an antihypertensive agent and has shown antioxidant properties. This study aims at determining the effects of captopril on factors affecting gastric mucosal integrity in aspirin-induced gastric lesions. Material and methods: Eighteen male Sprague-Dawley (200-250 g) rats that were given aspirin (40 mg/100 g body weight) were divided into three groups: the control, captopril (1 mg/100 g body weight daily) and ranitidine (2.5 mg/100 g body weight twice daily) groups. Ranitidine and captopril were given orally for 28 days. Rats in all groups were sacrificed and the parameters measured. Results: Captopril reduced gastric acidity, and increased gastric glutathione (GSH) and prostaglandin E2 (PGE2) significantly in comparison to the control group. Captopril also reduced malondialdehyde (MDA) and gastric lesions insignificantly compared to the control group. Ranitidine healed the lesions significantly compared to the control group. There was no difference between ranitidine and captopril on the severity of lesions, gastric acidity, MDA and GSH. Captopril increased PGE2 compared to ranitidine (p < 0.05). Conclusions: Captopril has desirable effects on the factors affecting gastric mucosal integrity (acidity, PGE2 and GSH) and is comparable to ranitidine in ulcer healing.

KW - Aspirin

KW - Captopril

KW - Gastric lesions

KW - Ranitidine

UR - http://www.scopus.com/inward/record.url?scp=84892399256&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84892399256&partnerID=8YFLogxK

U2 - 10.5114/aoms.2012.31252

DO - 10.5114/aoms.2012.31252

M3 - Article

AN - SCOPUS:84892399256

VL - 9

SP - 1132

EP - 1137

JO - Archives of Medical Science

JF - Archives of Medical Science

SN - 1734-1922

IS - 6

ER -